Target species
Dogs.
Indications for use
1Treatment of behavioural disorders of purely emotional origin: depression, anxiety.
2In association with behaviour therapy, treatment of signs of emotional origin observed in behavioural conditions such as over activity, separation problems, generalised phobia and unsociable behaviour.
Emotional disorders are characterised by a modification of feeding, drinking, auto-stimulatory behaviour, sleep, exploratory behaviour, aggression related to fear and/or irritation, social behaviour and somatic disorders (tachycardia, emotional micturition)
Contraindications
1Owing to its IMAO properties, (–) selegiline hydrochloride may act on prolactin secretion. In the absence of specific studies, it is recommended that the product should not be administered to pregnant and lactating bitches.
2Do not administer the product from the day before until the day after anaesthesia or tranquillisation performed with an alpha-2 agonist.
3Do not administer the product concomitantly with pethidine, fluoxetine or phenothiazines.
4The narcotic action of morphine is potentiated by the product.
Special warnings for each target species
If no clinical improvement is observed after 2 months, continuing the treatment is not likely to provide any additional benefit.
It is advisable to weigh animals before dosing to ensure the correct mg/kg dosage is administered.
Special precautions for use, including special precautions to be taken by the person administering the medicinal product to animals
Special precautions for use in animals
Emotional disorders can mask hierarchical conflicts. In dominant dogs suffering from an emotional disorder, the alleviation of the disorder can sometimes reveal a latent aggressiveness. In such cases, behavioural therapy must be instituted.
Special precautions to be taken by the person administering the medicinal product to animals:
In the event of accidental ingestion, seek medical advice and show the doctor the package leaflet.
Wash hands after use.
Adverse reactions (frequency and seriousness)
Trials have shown that some dominant dogs, with behavioural disorders but no signs of aggression, may become aggressive after treatment. Those previously showing aggression may have this enhanced. Appropriate training is essential in such cases.
Use during pregnancy, lactation or lay
It is recommend to stop the treatment during pregnancy and lactation.
Interaction with other medicinal products and other forms of interaction
1Do not administer the product from the day before until the day after an anaesthesia or tranquillisation performed with an alpha-2 agonist.
2Do not administer the product concomitantly with pethidine, fluoxetine or phenothiazines.
3The narcotic action of morphine is potentiated by the product.
Amounts to be administered and administration route
Selgian 4 mg:
Oral route: 0.5 mg/kg/day of (–) selegiline hydrochloride in a single administration.
Dog weight in kg | Number of tablets |
≥ 1.5 < 3 | ¼ |
≥ 3 < 5 | ½ |
≥ 5 < 7 | ¾ |
≥ 7 < 9 | 1 |
≥ 9 < 11 | 1¼ |
≥ 11 < 13 | 1½ |
≥ 13 < 15 | 1¾ |
≥ 15 < 17 | 2 |
Selgian 10 mg:
Oral route: 0.5 mg/kg/day of (–) selegiline hydrochloride in a single administration.
Dog weight in kg | Number of tablets |
≥ 8 < 12 | ½ |
≥ 12 < 17 | ¾ |
≥ 17 < 22 | 1 |
≥ 22 < 27 | 1¼ |
≥ 27 < 32 | 1½ |
≥ 32 < 37 | 1¾ |
≥ 37 < 42 | 2 |
Selgian 20 mg:
Route of administration: Oral use.
According to the dosage the tablet can be divided into 4.
0.42 mg/kg/day of selegiline, corresponding to 0.5 mg/kg/day selegiline hydrochloride (1 film-coated tablet 20 mg per 40 kg BW) in a single administration in the morning to fasting dogs.
Dog weight in kg | Number of tablets |
≥ 26 < 36 | ¾ |
≥ 36 < 46 | 1 |
≥ 46 < 56 | 1¼ |
≥ 56 < 66 | 1½ |
≥ 66 < 76 | 1¾ |
≥ 76 < 86 | 2 |
The treatment should be continued until the clinical condition is stable.
The minimum treatment period recommended is 2 months, based on the clinical trials results:
•The treatment period was 2 to 3 months for 20% of the dogs
•The treatment period was 4 to 5 months for 50% of the dogs
•The treatment period was 6 to 7 months for 20% of the dogs
•The treatment period was > 7 months for 10% of the dogs
The treatment can be stopped suddenly without gradual dose reductions.
Overdose (Symptoms, emergency procedures, antidotes)
Unlikely to occur.
Withdrawal periods
Not applicable.